Study procedures
toxicities, malignant ascites, Tumor, Cancer
ADVERSE EVENT, METASTASIS, TUMOR, ADVERSE EVENTS, DISEASE, SOLID TUMOR, MALIGNANT ASCITES, CANCER
The primary endpoint was 1‐year overall survival rate, and the second endpoints were PFS, OS, ORR, DCR, and adverse events. Physical examination, abdomen and chest CT were conducted to define the stage of disease, diagnose peritoneal metastasis and evaluate the efficacy every 3 cycles. Before each course of treatment, medical history, physical examination and laboratory examinations (blood cell count, liver and renal function tests, and serum tumor‐related markers including CEA, CA153, and CA125) were performed. Complete blood cell count and liver and renal function (including urinalysis) tests were performed weekly during the treatment. Laparoscopic exploration and gastroendoscopy were also performed when necessary. Tumor responses were assessed according to the Response Evaluation Criteria in Solid Tumor (RECIST) guidelines version 1.1, every 9 weeks. The number of malignant ascites and peritoneal cytology were also considered to evaluate the antitumor effects of the treatment on peritoneal metastasis. The incidence and severity of treatment toxicities were evaluated according to the National Cancer Institute‐Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).